Medical Cannabis 2026: What the Research Shows

A sweeping JAMA review (Hsu et al., 2026) examined over 2,500 cannabis-related scientific papers published between 2010 and 2025 (UCLA Health) and reached a conclusion that may surprise both advocates and opponents: "While many people turn to cannabis seeking relief, our review highlights significant gaps between public perception and scientific evidence regarding its effectiveness for most medical conditions." A separate 2026 Lancet Psychiatry analysis of 50+ randomized controlled trials found limited high-quality evidence for cannabis treating mental health conditions. This guide walks through every major condition, ranks the evidence honestly, explains the rescheduling situation as of October 2026 (medical marijuana moved to Schedule III in April 2026; the rest is still in a DEA hearing), and helps you have an informed conversation with your doctor.

As an Amazon Associate I earn from qualifying purchases.

The Schedule III rescheduling situation (October 2026)

There is significant confusion about the current legal status. Here's the timeline and reality:

August 2023: HHS recommended to DEA that marijuana be moved from Schedule I to Schedule III, concluding it has "currently accepted medical use" and lower abuse potential (DOJ proposed rule, 21 May 2024).

May 2024: DOJ published a proposed rule to reschedule on May 21, 2024 (Federal Register). Hearings were requested by multiple parties.

January 2025: On January 13, 2025, the DEA administrative law judge stayed the hearing pending an interlocutory appeal by two parties; the judge later retired and the proceeding stayed frozen until DEA withdrew it in April 2026 (DEA withdrawal notice).

December 18, 2025: President Trump signed Executive Order 14370 directing the Attorney General to "take all necessary steps to complete the rulemaking process related to rescheduling marijuana to Schedule III of the CSA in the most expeditious manner" (EO 14370, 90 FR 60541).

January 6, 2026: DEA publicly clarified that the rescheduling process "remains pending" and must still proceed through required administrative steps.

February 2026: Trump signed legislation preventing Washington D.C. from legalizing marijuana. AG Bondi reversed Biden-era possession amnesty and directed federal prosecution for personal possession.

April 22 to 28, 2026: Acting Attorney General Todd Blanche signed a final order, effective April 28, that moves marijuana in FDA-approved drug products and marijuana covered by a state medical marijuana license into Schedule III; adult-use marijuana, unlicensed bulk marijuana and synthetic THC stay in Schedule I, and hemp is unaffected (91 FR 22714). The same day DEA withdrew the stalled 2024 hearing and noticed a new one on moving the rest of marijuana to Schedule III, starting June 29, 2026 (hearing notice).

October 2026: As of October 19, 2026, no final rule on the rest of marijuana has been published in the Federal Register; the decision still sits with the DEA hearing process.

What this means in plain English: The executive order expressed intent, but did not by itself change marijuana's legal status; the April 2026 order did, in part. As of October 2026, marijuana under a state medical license or in an FDA-approved product is Schedule III, and all other marijuana remains Schedule I federally. The hearing on the rest could still produce a final rule, but as of October 19, 2026 none has been published, and experts describe the timing as uncertain. Legal experts note a contradiction between the executive order supporting rescheduling and the DOJ's simultaneous pursuit of possession charges. Cannabis policy analysts describe the situation as the administration supporting rescheduling "in words" while pursuing prohibition "in actions."

What Schedule III does (and doesn't) change, now that medical marijuana has moved: The April 2026 order formally recognizes cannabis's medical value, reduces research barriers (DEA-registered researchers may now source marijuana from state medical licensees), and lifts the Section 280E tax burden, but only for holders of state medical marijuana licenses; adult-use businesses remain under Schedule I and 280E (91 FR 22714). It does NOT legalize recreational marijuana, and it does not turn a dispensary into a pharmacy: a state medical licensee must first obtain a DEA registration, through a new expedited process, before it can manufacture, distribute or dispense marijuana under federal law. The FDA-approved cannabinoid medicines (Epidiolex, Marinol, Syndros, Cesamet) remain the only cannabis products available on an ordinary prescription (FDA).

Medical conditions ranked by evidence strength

Below is our evidence-ranked assessment of every major condition for which cannabis is commonly used or studied. These ratings reflect the consensus of the JAMA 2025 review, the Lancet Psychiatry 2026 analysis, and our own cross-referencing of individual RCTs. "Evidence" here means high-quality randomized controlled trials in humans, not animal studies, not anecdotes, not survey data.

Tier 1: Strong evidence (8-9/10)

Epilepsy (specifically Dravet and Lennox-Gastaut syndromes), 9.0/10

This is cannabis medicine's clearest success story. Epidiolex (purified CBD) is FDA-approved for seizure reduction in Dravet syndrome, Lennox-Gastaut syndrome, and tuberous sclerosis complex. Multiple large-scale RCTs demonstrated significant seizure reduction versus placebo. This is the only FDA-approved plant-derived cannabis medicine (FDA), approved for patients 1 year of age and older (Epidiolex label), and represents the gold standard for evidence in this space.

Chemotherapy-induced nausea and vomiting, 8.5/10

THC-based medicines (Marinol/dronabinol and Syndros) are FDA-approved for chemotherapy nausea. This was one of the earliest medical applications of cannabinoids and has decades of clinical evidence. Nabilone (Cesamet), a synthetic THC analog, is also approved for this indication (FDA). The evidence here is well-established, though the effect is modest: a meta-analysis of randomized trials cited in the 2026 JAMA review found a small but significant reduction in nausea and vomiting with prescribed cannabinoids (Hsu et al., JAMA 2026).

Chronic pain, 8.0/10

Chronic pain is the most common reason patients seek medical cannabis. The evidence base is substantial: multiple systematic reviews support modest but meaningful pain reduction with cannabis, particularly for neuropathic pain, which the 2026 JAMA review singles out as one of the few areas with some supporting evidence (UCLA Health). A clinical trial found that a balanced THC:CBD treatment reduced chronic temporomandibular disorder pain significantly, with functional pain dropping approximately 90%. However, the JAMA review notes that effect sizes are typically moderate, cannabis is not superior to all existing treatments, and long-term safety data remains limited. The evidence is strongest for neuropathic pain, moderate for inflammatory pain, and weakest for acute pain. For non-cannabis approaches to pain and inflammation, see our guides on omega-3 (anti-inflammatory) and curcumin (NF-kB inhibition).

Multiple sclerosis spasticity, 8.0/10

Sativex (nabiximols, a 1:1 THC:CBD oromucosal spray) is approved in 25+ countries (not the US) for MS-related spasticity. Clinical trials demonstrate meaningful spasticity reduction, and the 2026 JAMA review lists MS spasticity among the few uses with supporting evidence (UCLA Health). This is one of the most well-characterized therapeutic applications of full-spectrum cannabis medicine.

Tier 2: Moderate or emerging evidence (6-7.5/10)

Insomnia, 7.0/10

A 2026 clinical trial found that a cannabis-based herbal formula performed similarly to lorazepam (a benzodiazepine) for chronic insomnia, with additional benefits for sleep quality. CBD+THC combinations appear most effective for sleep, with CBD alone less effective than combinations. The trial base is thin, though: a 2026 Lancet Psychiatry meta-analysis found cannabinoids increased measured sleep time in insomnia but rated the evidence generally low quality (Wilson et al., 2026), and the 2026 JAMA review concluded randomized trials do not support cannabis for insomnia (Hsu et al., 2026). However, high-dose THC may disrupt REM sleep architecture with chronic use, potentially reducing sleep quality over time despite faster sleep onset. For non-cannabis sleep protocols with strong evidence and no REM disruption, see our Sleep Stack guide (magnesium, L-theanine, apigenin, glycine) and best sleep supplements.

Anxiety (acute, CBD-specific), 6.5/10

This is where the nuance matters enormously. The Lancet Psychiatry 2026 review found that "cannabinoids as a whole haven't been shown to be helpful for anxiety"; across 54 randomized trials it found no significant effects on anxiety outcomes (Wilson et al., 2026). But researchers note that picture changes when you look at specific compounds, CBD specifically has shown promise in several trials for acute anxiety reduction. THC, by contrast, can worsen anxiety at higher doses. For non-cannabis anxiety support, ashwagandha (KSM-66) has stronger evidence for chronic anxiety/stress reduction at lower cost and with a clearer safety profile.

Autism spectrum disorder (emerging), 6.0/10

CBDV (cannabidivarin) is being studied in multiple ongoing trials for reducing irritability and behavioral problems in children with ASD. Early results are promising but not yet definitive. The 2026 Lancet Psychiatry meta-analysis found a reduction in autistic traits with cannabinoids, on generally low-quality evidence (Wilson et al., 2026).

Tier 3: Weak or insufficient evidence (4-5.5/10)

Depression, 5.0/10

The Lancet Psychiatry review found no randomized controlled trial evidence at all for cannabis as a treatment for depression (Wilson et al., 2026). For evidence-based mood support, our Mood Stack covers ashwagandha, rhodiola, saffron, and omega-3, all with stronger controlled-trial evidence for mood improvement.

PTSD, 5.0/10

Despite PTSD being one of the most common qualifying conditions for medical cannabis in state programs, the controlled-trial evidence is limited: the 2026 Lancet Psychiatry meta-analysis found no significant effects on PTSD outcomes (Wilson et al., 2026). VA-funded trials are ongoing but have not yet produced definitive results.

ADHD, 4.5/10

Very limited controlled evidence. Some patients report symptom improvement, but the 2026 Lancet Psychiatry systematic review found too few trial data on ADHD even to run a meta-analysis (Wilson et al., 2026).

THC:CBD ratios: the pharmacology that actually matters

Cannabis's effects depend enormously on the ratio of THC to CBD. The same plant can be therapeutic or harmful depending on this ratio.

Safety: what the research says about risks

Cardiovascular risk

The JAMA review recommends that clinicians screen for cardiovascular disease before recommending THC-containing products (UCLA Health). THC temporarily increases heart rate and may affect blood pressure (NIDA). In the data the review cites, daily inhaled use was associated with more coronary heart disease (2.0% vs 0.9%), heart attack (1.7% vs 1.3%) and stroke (2.6% vs 1.0%) than nondaily use (Hsu et al., JAMA 2026). If you have heart disease, raise this with your prescriber before any THC product.

Psychosis and mental health risk

A 2025 review of nearly 100 studies found strong links between high-potency cannabis (high-THC products) and psychosis, schizophrenia, and cannabis use disorder. The risk increases with potency, frequency of use, and younger age of onset: in the adolescent data cited by the 2026 JAMA review, high-potency use was associated with psychotic symptoms in 12.4% vs 7.1% for low-potency use (Hsu et al., 2026), and a 2026 Lancet Psychiatry review found credible evidence that daily use is a contributory cause of psychosis (Hall et al., 2026). CBD may be protective against psychosis, but that is not settled: NCCIH notes CBD may also produce psychotic effects or cognitive impairment in people who also regularly use THC (NCCIH).

Cognitive effects

Regular THC use is associated with impairments in working memory, attention, and processing speed, particularly with adolescent onset (NIDA). These effects are at least partially reversible with abstinence. For evidence-based cognitive enhancement without these risks, see our Cognitive Stack and Lion's Mane guide.

Drug interactions

Both THC and CBD interact with CYP450 enzymes. CBD in particular is a moderate inhibitor of CYP2C19 and a weak inhibitor of CYP1A2, and strong CYP3A4 or CYP2C19 inducers lower CBD levels; the Epidiolex label advises dose changes for drugs cleared by CYP2C19, CYP1A2, CYP2C8, CYP2B6 and UGT1A9 (Epidiolex label). NCCIH adds that CBD use has been associated with liver injury and interactions with other drugs (NCCIH), so tell your prescriber and pharmacist before combining CBD with any regular medication. This interaction concern is shared with several herbal supplements, berberine and curcumin with BioPerine similarly affect CYP enzymes.

Cannabis use disorder

Older dependence estimates put it at approximately 9% of people who use cannabis (rising to 17% among those who start in adolescence); using today's broader cannabis use disorder definition, NIDA reports that studies estimate 22% to 30% of people who use cannabis have the disorder (NIDA), and the 2026 JAMA review found 29% of people using cannabis for medical purposes met the criteria (Hsu et al., 2026).

FDA-approved cannabinoid medicines

Cannabis vs. Health Britannica supplement alternatives by condition

How to talk to your doctor about medical cannabis

Be specific about your condition and what you've tried. "I have chronic neuropathic pain that hasn't responded to X and Y" is far more useful than "I want a medical marijuana card."

Ask about THC:CBD ratios. For anxiety and inflammation, CBD-dominant products (<=1:6 ratio) have better safety profiles. For pain, balanced ratios may be more effective but carry more side effects.

Disclose all medications and supplements. Cannabis interacts with many common drugs through CYP450 enzymes. This includes supplements like berberine and curcumin with BioPerine.

Start low, go slow. Begin with the lowest available dose and increase gradually under medical supervision.

Track your outcomes. Keep a simple log of dose, timing, symptom relief, and side effects.

Sources

1. Federal Register. Rescheduling of FDA-Approved Products Containing Marijuana From Schedule I to Schedule III (91 FR 22714). Accessed 19 October 2026.
2. Federal Register. Schedules of Controlled Substances: Rescheduling of Marijuana (hearing notice, 28 April 2026). Accessed 19 October 2026.
3. Federal Register. Schedules of Controlled Substances: Rescheduling of Marijuana; Withdrawal. Accessed 19 October 2026.
4. Federal Register. Schedules of Controlled Substances: Rescheduling of Marijuana (proposed rule, 21 May 2024). Accessed 19 October 2026.
5. Federal Register. Executive Order 14370, Increasing Medical Marijuana and Cannabidiol Research. Accessed 19 October 2026.
6. Federal Register. Implementation of the Agriculture Improvement Act of 2018 (85 FR 51639). Accessed 19 October 2026.
7. Congressional Research Service. Changes to the Statutory Definition of Hemp and Implications for Agricultural Policy (IF13136). Accessed 19 October 2026.
8. FDA. FDA and Cannabis: Research and Drug Approval Process. Accessed 19 October 2026.
9. FDA. FDA Regulation of Cannabis and Cannabis-Derived Products, Including Cannabidiol (CBD). Accessed 19 October 2026.
10. DailyMed. Epidiolex (cannabidiol) oral solution, prescribing information. Accessed 19 October 2026.
11. Hsu M, et al. Therapeutic Use of Cannabis and Cannabinoids: A Review. JAMA, 2026. Accessed 19 October 2026.
12. Wilson J, et al. The efficacy and safety of cannabinoids for the treatment of mental disorders and substance use disorders. Lancet Psychiatry, 2026. Accessed 19 October 2026.
13. Hall W, et al. Relationships between cannabis use and mental disorders. Lancet Psychiatry, 2026. Accessed 19 October 2026.
14. UCLA Health. Evidence lacking for medical cannabis in most conditions. Accessed 19 October 2026.
15. ScienceDaily (UCLA Health release). Scientists reveal the real benefits and hidden risks of medical cannabis. Accessed 19 October 2026.
16. NIDA. Cannabis (Marijuana). Accessed 19 October 2026.
17. NCCIH. Cannabis (Marijuana) and Cannabinoids: What You Need To Know. Accessed 19 October 2026.
18. eCFR. 21 CFR Part 1308, Schedules of Controlled Substances. Accessed 19 October 2026.

Bottom line

Medical cannabis is neither the miracle cure its advocates claim nor the menace its opponents fear. The evidence is genuinely strong for a handful of conditions, epilepsy (Epidiolex is FDA-approved), chemotherapy nausea (Marinol has decades of data), neuropathic pain (multiple systematic reviews), and MS spasticity (Sativex is approved in 25+ countries). For these conditions, cannabinoid medicines represent real therapeutic options.

For the conditions that drive most consumer interest, anxiety, depression, sleep, general wellness, the evidence is notably weaker. For these conditions, the Mood Stack, Sleep Stack, and evidence-based herbal alternatives like ashwagandha, saffron, and Lion's Mane often have equal or stronger controlled-trial evidence with fewer side effects.

The rescheduling situation is half-finished: as of October 2026, state-licensed medical marijuana and FDA-approved marijuana products are Schedule III, while the rest of marijuana still awaits the DEA hearing. Whatever happens legislatively, the science will continue to clarify which patients benefit most from which cannabinoid compounds at which ratios. Health Britannica will continue to cover this research honestly, including the findings that don't match the narrative on either side.